Breaking News

MedDay Boosts its Research Capabilities

Acquisition of Profilomic SA health division fuels the growth of MedDay

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

MedDay, a biotechnology company focused on the treatment of nervous system disorders, has boosted its research platform by acquiring the health division of Profilomic SA, a company formed out of Commissariat à l’Energie Atomique (CEA) in 2010. The acquisition will allow MedDay to strengthen its existing metabolomics research platform, SPECMET, with the aim of expanding its pipeline of neurological disorder therapies. MedDay has acquired all of the health-related assets from Profilomic, ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters